Delayed postoperative radiotherapy might improve the long-term prognosis of locally advanced esophageal squamous cell carcinoma

Ming-qiang Lin a,1, Jin-luan Li a,1, Zong-kai Zhang b, Xiao-hui Chen a, Jia-ju Ma a, Ya-qing Dai b, Shu-yun Huang a, Yi-bin Hu a, Jian-cheng Li a,n

a Department of Radiation Oncology, Fufan Cancer Hospital and Fujian Medical University Cancer Hospital, 420 Fuma Rd, Jin’an District, Fuzhou, Fujian 350014, China
b Department of Radiation Oncology, Xiamen Cancer Center, The First Affiliated Hospital, School of Medicine, Xiamen University, Xiamen 361003, China

ARTICLE INFO

Keywords:
Esophageal squamous cell carcinoma
Postoperative radiotherapy
Time intermission

ABSTRACT

Objective: There is no consensus on the optimal timing of postoperative radiotherapy (PORT) for locally advanced esophageal squamous cell carcinoma (ESCC). We aimed to determine whether the timing of PORT affects the long-term prognosis of ESCC, and plotted nomograms to predict survival.

Methods: We retrospectively analyzed 351 ESCC patients who underwent radical surgery and PORT. Receiver operating characteristic curves were used to estimate the optimal cutoff point of the time interval between surgery and PORT. Cox proportional hazards regression was used to identify prognostic predictors. Overall survival (OS) and progression-free survival (PFS) were predicted using nomograms.

Results: The median follow-up was 53 months (range: 3–179 months). Compared to early PORT, PORT at >48 days after surgery was associated with better OS (adjusted hazard ratio [HR]: 1.406, p = 0.037) and PFS (adjusted HR: 1.475, p = 0.018). In the chemotherapy subgroup, incorporation of chemotherapy timing into the analysis suggested that 2–4 chemotherapy cycles followed by PORT was the optimal treatment schedule as compared to 0–1 chemotherapy cycle followed by PORT and concurrent chemoradiotherapy (5-year PFS: 65.9% vs. 51.0% vs. 50.1%; p = 0.049). The nomograms for OS and PFS were superior to the TNM classification (concordance indices: 0.721 vs. 0.626 and 0.716 vs. 0.610, respectively).

Conclusions: Delayed PORT (>48 days) provides better survival benefit than early PORT among ESCC patients. PORT following 2–4 chemotherapy cycles might lead to the best survival rate. The nomogram plotted in this study effectively predicted survival and may help guide treatment.

Introduction

According to GLOBOCAN 2018, esophageal cancer is the seventh most common cancer worldwide and the sixth leading cause of death; every year, there are more than 572,000 new cases of esophageal cancer worldwide, with more than 508,000 deaths [1]. Approximately half of all new cases are diagnosed in China [2]. Fortunately, however, advances in the detection and treatment of esophageal cancer have led to an increase in the likelihood of survival between 2000 and 2018 [3].

Surgery is the mainstay of treatment for resectable esophageal cancer. However, almost 40% of patients who undergo surgery alone develop locoregional recurrence, and almost 30% of them develop distant metastases, with no significant difference between the timing of locoregional recurrence and the timing of systemic recurrence [4]. Many studies have shown that compared with surgery alone, surgery followed by radiotherapy or chemoradiotherapy is associated with better locoregional control and longer survival [5–7]. However, the prognostic implications of the time interval between surgery and postoperative radiotherapy (PORT) are not well established, and the optimal time for...
initiating radiation after surgery so as to maximize patient survival remains an open question.

Studies on the effects of the time interval between radiotherapy and surgery for esophageal cancer have mainly focused on the interval between neoadjuvant radiotherapy and surgery [8–10]. Few studies have explored the effects of the interval between surgery and PORT [11,12], and important confounding factors such as the number of lymph nodes removed and the sequence of postoperative adjuvant treatments, which may account for prognostic differences, have been ignored. Although the interval between surgery and PORT has been more thoroughly studied for other malignancies, the results obtained have been mixed [13–15]. The optimal timing of PORT after surgery for locally advanced esophageal squamous cell carcinoma (ESCC) is important for clinicians to establish a treatment strategy, but remains to be reliably determined. Therefore, the present study aimed to determine the survival impact of the timing of PORT after surgery for ESCC and to develop a new prognostic model to predict the 5-year overall survival (OS) and progression-free survival (PFS).

Materials and methods

Patients

The study subjects consisted of 351 patients with locally advanced ESCC who underwent complete resection (R0 resection) and PORT at Fujian Cancer Hospital between June 2006 and June 2016. The time interval between the surgery and PORT as well as other clinical data were retrospectively collected. The inclusion criteria were pathologically proven squamous cell carcinoma, R0 resection with negative margins, and surgery followed by PORT. The exclusion criteria were neoadjuvant radiotherapy, PORT performed after tumor recurrence or metastasis, unknown interval between surgery and PORT, incomplete outcome data, and a second malignant primary cancer.

Data collection

The following patient- and tumor-related factors were collected: age, sex, comorbidities, tumor location, tumor differentiation, pathological T (pT) classification, pathological N (pN) classification, tumor length, the number of positive lymph nodes, vascular tumor emboli, and nerve invasion. The treatment-related characteristics included neoadjuvant chemotherapy, surgical approach, number of lymph nodes removed, postoperative complications, adjuvant chemotherapy, time interval between surgery and PORT, radiation technology, and radiation dose. We also calculated the lymph node ratio (LNR), which was defined as the ratio of positive to removed lymph nodes. We used the 8th edition of the American Joint Committee on Cancer (AJCC) staging system to reclassify all patients in our study.

Statistical analysis

The primary outcome measure was OS, and the secondary outcome measure was PFS. OS was measured from the date of the surgery to the date of death from any cause or the date of the last follow-up. PFS was measured from the date of the surgery to the date on which evidence of tumor progression was found, the date of death from any cause, or the date of the last follow-up. Continuous data were compared using the Wilcoxon-Mann-Whitney nonparametric test. Categorical data were compared using the Pearson chi-square test or the Fisher exact test. Since the clinical interpretation and application of hazard ratios (HRs) is easier, the time interval was analyzed as a categorical variable rather than a continuous variable. Receiver operating characteristic (ROC) curve analysis was conducted to estimate the optimal cutoff points for the time interval between surgery and PORT, and the LNR. Differences in OS and PFS between groups were assessed using log-rank tests and demonstrated using Kaplan-Meier curves. The clinicopathological and treatment-related factors collected were subjected to univariate Cox analysis. Those factors with \( p < 0.10 \) in the univariate Cox analysis were then incorporated into the multivariate Cox analysis to identify independent predictors of survival. All tests were two-sided, and \( p < 0.05 \) was considered significant. All statistical analyses were performed using SPSS v25.0 (IBM Inc., Armonk, NY, USA).

Nomogram construction and validation

Using the results of the multivariate Cox analysis, we constructed nomograms integrating all the independent prognostic factors. The 5-year OS and PFS rates were predicted using the rms packages of the R software (version 4.0.1). The Harrell concordance index (C-index) and the area under the ROC curve (AUC) were used to test the prognostic accuracy of the model among patients with locally advanced ESCC after radical resection and PORT. The consistency between the actual observed survival rates and the predicted survival rates was evaluated using calibration curves. Bootstrapping with 1000 re-samples was used to evaluate both the discrimination and calibration of the model.

Results

Patient characteristics

A total of 351 patients were included in this study. On the basis of the ROC curves for both OS and PFS, we divided the time interval between surgery and PORT as a dichotomous variable at a cutoff point of 48 days. Thus, patients were divided into an early PORT group (≤48 days) and a delayed PORT group (>48 days). The baseline demographic, tumor, and treatment characteristics of the patients in the two groups are listed in Table 1. The median interval between surgery and PORT was 57 days (range: 19–160 days). The median follow-up period from the date of the surgery to the date of death or the last follow-up was 53 months (range: 3–179 months). At the first diagnosis, 69.23% of patients were aged less than 60 years. In all, 78.63% of the patients were male, and 60.40% of the tumors were located in the middle third of the esophagus. The most common pT and pN classifications were pT3 (56.98%) and pN1 (48.72%). The optimal cut-off value for LNR calculated using ROC curves was 0.075, patients with LNR < 0.075 accounted for 56.70%. The patients in the delayed PORT (>48 days) group had a higher proportion of postoperative complications (27.16% vs. 5.56%, \( p < 0.001 \)), greater number of lymph nodes removed (median, 33 vs. 29, \( p = 0.002 \)), and a higher probability of pN+ disease (72.02% vs. 60.19%, \( p < 0.004 \)) than those in the early PORT (≤48 days) group.

Progression-free survival

The 5-year PFS was 52.5% (95% confidence interval [CI]: 0.472–0.578), and the median PFS was 48 months (range: 2–173 months). The interval between surgery and PORT significantly influenced the PFS (Fig. 1A). The 5-year PFS rates in the early and delayed PORT groups were 41.0% (95% CI: 0.316–0.504) and 58.0% (95% CI: 0.517–0.643; \( p < 0.001 \)), respectively.

The results of the univariate and multivariate Cox regression analyses of factors influencing PFS are shown in Table 2. On univariate Cox regression analysis, initiation of PORT at ≤48 days after surgery was associated with a 1.7-fold increase in the probability of tumor progression (HR: 1.703, 95% CI: 1.256–2.309; \( p = 0.001 \)) in comparison with initiation of PORT after 48 days. Multivariate Cox regression analysis showed that in comparison with a time to PORT of >48 days, a time to PORT of ≤48 days was associated with a 1.5-fold increase in the probability of tumor progression (adjusted HR: 1.475, 95% CI: 1.068–2.037; \( p = 0.018 \)). Additional factors associated with a poorer PFS were male sex as compared to female sex (adjusted HR:
Table 1
Demographic, clinicopathological, and treatment characteristics of patients.

| Variable                        | ≤ 48 days n = 108 (%) | > 48 days n = 243 (%) | p      |
|---------------------------------|-----------------------|-----------------------|--------|
| Age (years)                     | ≤ 60                  | > 60                  | 0.418  |
|                                 | 78 (72.22)            | 165 (67.90)           |        |
|                                 | ≥ 60                  |                       |        |
|                                 | 30 (27.78)            | 78 (32.10)            |        |
| Sex                             | Male                  | Female                | 0.152  |
|                                 | 90 (83.33)            | 18 (16.67)            |        |
|                                 |                       |                       |        |
| Comorbidities                   | No                    | Yes                   | 0.895  |
|                                 | 86 (79.63)            | 22 (20.37)            |        |
|                                 |                       |                       |        |
| Tumor location                  | Upper                 | Middle                | 0.686  |
|                                 | 30 (27.78)            | 64 (59.26)            |        |
|                                 |                       |                       |        |
| Tumor differentiation           | Poor                  | Moderate              |        |
|                                 | 12 (11.11)            | 85 (78.70)            |        |
|                                 |                       |                       |        |
| pT classification               | 1                     | 2                     | 0.588  |
|                                 | 3 (2.78)              | 17 (15.74)            |        |
|                                 |                       |                       |        |
| pN classification               | 0                     | 1                     | 0.004  |
|                                 | 43 (39.81)            | 54 (50.00)            |        |
|                                 |                       |                       |        |
| Number of positive lymph nodes  | Mean ± SD             |                       | 0.136  |
|                                 | 2.70 ± 1.89           | 2.99 ± 3.97           |        |
|                                 | Median                | 1.50                  |        |
|                                 |                       | 2.00                  |        |
| Number of lymph nodes removed   | Mean ± SD             |                       | 0.002  |
|                                 | 29.54 ± 11.77         | 34.47 ± 13.62         |        |
|                                 | Median                | 29.00                 |        |
|                                 |                       | 33.00                 |        |
| LNR                             | < 0.075               | ≥ 0.075               | 0.715  |
|                                 | 63 (58.33)            | 45 (41.67)            |        |
|                                 |                       |                       |        |
| Tumor length (cm)               | Mean ± SD             |                       | 0.301  |
|                                 | 4.50 ± 1.65           | 4.30 ± 1.58           |        |
|                                 | Median                | 4.00                  |        |
|                                 |                       | 4.00                  |        |
| Vascular tumor emboli           | No                    | Yes                   | 0.560  |
|                                 | 78 (72.22)            | 30 (27.78)            |        |
|                                 |                       |                       |        |
| Nerve invasion                  | No                    | Yes                   | 0.130  |
|                                 | 98 (90.74)            | 10 (9.26)             |        |
|                                 |                       |                       |        |
| Neoadjuvant chemotherapy        | No                    | Yes                   | 0.764  |
|                                 | 99 (91.67)            | 9 (8.33)              |        |
|                                 |                       |                       |        |
| Surgical approach               | Open                  | Endoscopic            | 0.006  |
|                                 | 76 (70.37)            | 32 (29.63)            |        |
|                                 |                       |                       |        |
| Postoperative complications      | No                    | Yes                   | < 0.001|
|                                 | 102 (94.44)           | 6 (5.56)              |        |
|                                 |                       |                       |        |
| Adjuvant chemotherapy           | No                    | Yes                   | 0.001  |
|                                 | 32 (29.63)            | 76 (70.37)            |        |
|                                 |                       |                       |        |
| Radiation technology            | 2D                    | 3D                    | < 0.001|
|                                 | 76 (70.37)            | 32 (29.63)            |        |
|                                 |                       |                       |        |
| Radiation dose (cGy)            | Mean ± SD             |                       | 0.308  |
|                                 | 5125.09 ± 322.64      | 5110.40 ± 312.23      |        |
|                                 | Median                | 5000                  |        |
|                                 |                       | 5000                  |        |

SD, standard deviation; pT classification, pathological T classification; pN classification, pathological N classification; LNR, lymph node ratio; 2D, two dimensional; 3D, three dimensional.

Fig. 1. Kaplan-Meier curves according to time interval categories for the whole study population (univariate analysis) showing (A) progression-free survival (p < 0.001) and (B) overall survival (p = 0.002).
Table 2
Factors associated with progression-free survival: univariate and multivariate Cox proportional hazards models.

| Variable                        | n | Univariate Analysis | Multivariate Analysis |
|---------------------------------|---|--------------------|-----------------------|
|                                 |   | HR | 95% CI | p      | HR | 95% CI | p      |
| Age (years) <60/ >60            | 243/108 | 0.703 | 0.516–0.959 | 0.026 | 0.764 | 0.549–1.064 | 0.111 |
| Sex                             | 276/75 | 1.770 | 1.174–2.701 | 0.006 | 1.611 | 1.050–2.473 | 0.029 |
| Male/female                     | 278/73 | 0.754 | 0.532–1.068 | 0.112 | –     | –       | –     |
| Comorbidities                   | 88/263 | 0.898 | 0.634–1.271 | 0.543 | –     | –       | –     |
| Tumor location                  | 44/307 | 0.971 | 0.609–1.548 | 0.902 | –     | –       | –     |
| Poor/well and moderate           | 72/279 | 0.602 | 0.396–0.914 | 0.017 | 0.769 | 0.496–1.192 | 0.241 |
| pT classification               | 518 | 0.358 | 0.263–0.463 | <0.001 | 0.683 | 0.427–1.090 | 0.110 |
| pN classification               | 111/240 | 0.739 | 0.516–1.048 | 0.820 | –     | –       | –     |
| Number of positive lymph nodes  | 351 | 1.083 | 1.057–1.110 | <0.001 | 1.057 | 1.018–1.097 | 0.001 |
| Number of lymph nodes removed   | 351 | 0.984 | 0.972–0.996 | 0.008 | 0.984 | 0.969–0.999 | 0.016 |
| LNR                              | 119/152 | 0.358 | 0.263–0.463 | <0.001 | 0.532 | 0.345–0.812 | 0.004 |
| N0/N1 and N2 and N3             | 111/240 | 1.003 | 0.999–1.007 | 0.028 | 1.003 | 1.000–1.007 | 0.028 |
| Vascular tumor emboli           | 69/209 | 0.947 | 0.805–1.010 | 0.021 | 0.991 | 0.859–1.099 | 0.200 |
| Nerve invasion                  | 246/105 | 1.008 | 0.644–1.577 | 0.973 | –     | –       | –     |
| Neoadjuvant chemotherapy        | 324/27 | 1.184 | 0.643–2.181 | 0.588 | –     | –       | –     |
| Surgical approach               | 160/120 | 1.600 | 1.159–2.110 | 0.004 | 1.439 | 1.023–2.024 | 0.037 |
| Postoperative complications     | 279/72 | 1.081 | 0.739–1.610 | 0.004 | 1.439 | 1.023–2.024 | 0.037 |
| Adjacent chemotherapy           | 68/283 | 1.391 | 0.976–1.982 | 0.004 | 1.814 | 1.219–2.698 | 0.003 |
| Radiation technology            | 188/163 | 1.116 | 0.822–1.515 | 0.483 | –     | –       | –     |
| Radiation dose (cGy)            | 108/243 | 1.001 | 1.000–1.001 | 0.001 | 1.000 | 1.000–1.001 | 0.001 |
| Time interval (days) ≤48        | 1.703 | 1.256–2.309 | 2.037 |

HR, hazard ratio; 95% CI, 95% confidence interval; pT classification, pathological T classification; pN classification, pathological N classification; LNR, lymph node ratio; 2D, two dimensional; 3D, three dimensional.

1.611, 95% CI: 1.050–2.473; p = 0.029), each increment in the number of positive lymph nodes (adjusted HR: 1.057, 95% CI: 1.018–1.097; p = 0.004), each increment in tumor length (adjusted HR: 1.143, 95% CI: 1.037–1.259; p = 0.007), open approach as compared to endoscopic approach (adjusted HR: 1.439, 95% CI: 1.023–2.042; p = 0.037), no adjuvant chemotherapy as compared to adjuvant chemotherapy (adjusted HR: 1.814, 95% CI: 1.219–2.698; p = 0.003), and each increment in radiation dose (adjusted HR: 1.001, 95% CI: 1.000–1.001; p = 0.007). Factors associated with improved PFS were each increment in the number of lymph nodes removed (adjusted HR: 0.984, 95% CI: 0.969–0.999; p = 0.036) and LNR < 0.075 as compared to LNR ≥ 0.075 (adjusted HR: 0.532, 95% CI: 0.345–0.820; p = 0.004).

Overall survival

The 5-year OS was 54.1% (95% CI: 0.488–0.594), and the median OS was 53 months (range: 3–179 months). The time interval between surgery and PORT significantly affected OS (Fig. 1B). The 5-year OS rates in the early and delayed PORT groups were 44.6% (95% CI: 0.352–0.540) and 58.6% (95% CI: 0.521–0.651; p = 0.002), respectively.

The results of the univariate and multivariate Cox regression analyses of factors influencing OS are shown in Table 3. On univariate Cox regression analysis, early PORT was associated with a 1.6-fold increase in mortality (HR: 1.613, 95% CI: 1.192–2.189; p = 0.002) in comparison with delayed PORT. Multivariate Cox regression showed that in comparison with a time to PORT of >48 days, a time to PORT of ≤48 days was associated with a 1.4-fold increase in mortality (adjusted HR: 1.406; 95% CI: 1.020–1.938; p = 0.037). Additional factors associated with poorer OS were male sex as compared with female sex (adjusted HR: 1.539, 95% CI: 1.003–2.362; p = 0.048), each increment in the number of positive lymph nodes (adjusted HR: 1.048, 95% CI: 1.011–1.087; p = 0.012), each increment in tumor length (adjusted HR: 1.156, 95% CI: 1.048–1.275; p = 0.004), open approach as compared to endoscopic approach (adjusted HR: 1.466, 95% CI: 1.042–2.063; p = 0.028), no adjuvant chemotherapy as compared to adjuvant chemotherapy (adjusted HR: 2.025, 95% CI: 1.350–3.038; p = 0.001), and each increment in radiation dose (adjusted HR: 1.001, 95% CI: 1.000–1.001; p = 0.002). Additional factors associated with improved OS were classification N0 to classification N1–N3 (adjusted HR: 0.597, 95% CI: 0.371–0.960; p = 0.033), each increment in the number of lymph nodes removed (adjusted HR: 0.982, 95% CI: 0.967–0.997; p = 0.020), and LNR < 0.075 as compared to LNR ≥ 0.075 (adjusted HR: 0.539, 95% CI: 0.350–0.830; p = 0.005).

Prediction nomogram for conditional survival

We plotted prognostic nomograms integrating all the independent predictors of PFS (Fig. 2) and OS (Fig. 3). Each factor was assigned points according to its coefficient. The 5-year PFS and OS rates were predicted by the sum of these points. The discriminative ability of the nomograms was compared with that of the 8th AJCC TNM classification. Our prediction model had an optimism-adjusted C-statistic for OS of 0.721 (95% CI: 0.684–0.758), which was superior to that of the 8th AJCC TNM classification (0.626, 95% CI: 0.589–0.662). The C-index for PFS (0.716, 95% CI: 0.68–0.75) was also superior to that
Table 3
Factors associated with overall survival: univariate and multivariate Cox proportional hazards models.

| Variable                        | n  | Univariate Analysis | Multivariate Analysis |
|----------------------------------|----|---------------------|-----------------------|
| Age (years) ≤50/ >60             | 243/108 | 0.660 (0.484–0.900) | 0.009 (0.796–0.569) | 0.185 |
| Sex                              | 1.739 (1.153–2.623) | 0.008 (1.539–1.103) | 0.003 (1.103–1.140) | 0.048 |
| Male/female                      | 0.743 (0.524–1.054) | 0.096 (0.748–0.514) | 0.011 (0.478–0.514) | 0.131 |
| Comorbidities No/yes             | 0.908 (0.641–1.385) | 0.585              | –                     |       |
| Tumor location Upper/middle and lower | 88/263 | 1.285              | –                     |       |
| Tumor differentiation Poor/well and moderate | 44/307 | 1.525              | –                     |       |
| pT classification T1 and T2/T3 and T4 | 72/279 | 0.886              | –                     |       |
| pN classification N0/N1 and N2 and N3 | 111/240 | 0.696              | –                     |       |
| Number of positive lymph nodes ≤0.075 | 199/152 | 0.494              | –                     |       |
| Vascular tumor emboli No/yes     | 0.652 (0.477–0.908) | 0.008 (0.930–0.658) | 0.682 |
| Nerve invasion No/yes             | 0.952 (0.608–0.830) | 0.011 (0.982–0.972) | 0.020 |
| Neoadjuvant chemotherapy No/yes   | 1.127 (0.612–0.701) | 0.009 (1.466–1.042) | 0.028 |
| Surgical approach Open/endoscopic | 1.546 (1.118–2.138) | 0.009 (2.063–2.063) | –       |
| Postoperative complications No/yes | 1.000 (0.683–0.999) | 0.047 (2.025–2.025) | 0.001 |
| Adjuvant chemotherapy No/yes      | 1.432 (1.004–2.042) | 0.047 (2.025–2.025) | 0.038 |
| Radiation technology 2D/3D        | 1.085 (0.799–0.602) | 0.002 (0.478–0.478) | 0.037 |
| Radiation dose (cGy) ≤48/ >48     | 1.615 (1.192–2.189) | 0.002 (1.406–1.406) | 0.002 |

HR, hazard ratio; 95% CI, 95% confidence interval; pT classification, pathological T classification; pN classification, pathological N classification; LNR, lymph node ratio; 2D, two dimensional; 3D, three dimensional.

Fig. 2. Nomogram predicting the 5-year PFS rate of patients with ESCC after radical surgery. The nomogram added up the points identified on the scale for each independent variable. The total points projected on the bottom scale indicate the probabilities of 5-year PFS rates. PFS, progression-free survival; ESCC, esophageal squamous cell carcinoma; LNR, lymph node ratio.
of the 8th AJCC TNM staging (0.610, 95% CI: 0.57199–0.64892). Furthermore, AUC models were used to evaluate the prognostic accuracy of the nomograms (Fig. 4). For predicting the 5-year PFS rate, the AUC of our nomogram was significantly greater than that of the AJCC staging system (0.771 vs. 0.609, p < 0.001). For predicting the 5-year OS rate, the AUC of our nomogram was also significantly greater than that of the AJCC staging (0.761 vs. 0.609, p < 0.001).

Calibration curves were generated to validate the consistency between the actual observed survival rates and the survival probability predicted using the nomograms (Fig. 5). The results indicated that the nomograms were well calibrated.

**Survival stratified by chemotherapy**

We found that adjuvant chemotherapy was an independent prognostic factor. Among the patients who received adjuvant chemotherapy, both PFS (p = 0.008) and OS (p = 0.014) significantly differed between the early and delayed PORT groups (Fig. 6A and 6B). In our study,
99 patients received concurrent chemoradiotherapy, and 184 patients received sequential chemoradiotherapy. In the sequential chemoradiotherapy group, the number of patients who did not undergo chemotherapy before PORT and those who underwent 1, 2, 3, or 4 cycles of chemotherapy before PORT were 10, 93, 51,16, and 14, respectively. After incorporating chemotherapy timing into our analysis, we found that treatment with 2–4 cycles of chemotherapy followed by PORT was associated with the best PFS (median PFS: 58 months, 5-year PFS: 65.9%; \( p = 0.049 \)), followed by 0–1 cycles of chemotherapy before PORT (median PFS: 46.5 months, 5-year PFS: 51.0%) and concurrent chemoradiotherapy (median PFS: 42 months, 5-year PFS: 50.1%). However, these subgroups did not show significant differences in OS (\( p = 0.09 \)).

**Discussion**

Adjuvant therapy for locally advanced esophageal cancer is very important, though the optimal timing of PORT in patients who have undergone radical resection of esophageal cancer remains to be determined. In the present study, after adjustments for numerous confounding factors, we found that initiating PORT ≥48 days after the surgery was associated with a better OS (adjusted HR: 1.406, \( p = 0.037 \)) and PFS (adjusted HR: 1.475, \( p = 0.018 \)). To the best of our knowledge, this is the first study to include the time interval between surgery and PORT for locally advanced ESCC in nomograms.

Two studies have previously attempted to explore the influence of the time interval between surgery and PORT on the survival of patients with esophageal cancer [11,12]. A retrospective study by Yamada et al. showed a higher mortality rate among patients who received PORT after 40 days after surgery than among those who started PORT within 40 days, though the difference in mortality was not significant [12]. In another retrospective study, Wang et al. reported that a delay in initiating PORT of longer than 26 days did not appear to have a survival cost, but a delay of longer than 42 days had a detrimental impact on OS [11]. The inconsistencies in the above results and those of our study may be attributable to differences in both patient composition and confounding factors. All patients enrolled in our study had squamous cell carcinoma. Furthermore, we found that some confounding factors, such as LNR and surgical approach, were also independent prognostic factors for survival. Although the majority of the patients in our present study and the two studies cited above received adjuvant chemoradiotherapy, the above two studies did not consider the effects of the sequence of adjuvant radiotherapy and chemotherapy, so they did not have sufficient evidence to draw reliable conclusions. Furthermore, the discriminative
ability of the nomogram constructed in this study showed a clear prognostic superiority over the 8th AJCC staging (C-index for OS: 0.721 vs. 0.626, C-index for PFS: 0.716 vs. 0.610).

Studies on the time interval between surgery and PORT for some other tumors have shown no survival benefit to starting PORT too early [14,16]. A retrospective study of head and neck cancer by Graboyes et al. found that early radiation was not associated with improved survival, as compared to initiating PORT 5–6 weeks after surgery [14]. Sura et al. retrospectively evaluated patients with pN2 non-small-cell lung cancer who underwent adjuvant chemoradiotherapy after surgery, and demonstrated that a time to radiation of ≥8 weeks with sequential chemotherapy was associated with improved survival [16]. Consistent with the above results, our data showed a superior OS of 58.6% and a superior PFS of 58% for delayed PORT (≥48 days) as compared to 44.6% and 41.0%, respectively, for early PORT (<48 days). The potential mechanisms underlying the association between early radiotherapy and poor prognosis may include the following: (1) early radiotherapy impedes wound healing; (2) poor shrinkage in the surgical area leads to a larger target volume for radiation therapy; (3) hypoxia in the tissue surrounding the surgical bed induces tumor resistance [17]; and (4) it may be more beneficial to perform another adjuvant therapy before PORT.

With a single predictor, such as the AJCC staging system, it is difficult to accurately predict the prognosis of ESCC after surgical resection. As other important prognostic factors are not considered, patients with the same tumor stage may have different clinical outcomes. In our nomogram, specific predicted 5-year OS and PFS rates were assigned for each total score, which may help clinical decision-making. A survival nomogram of esophageal cancer patients undergoing radical surgery has been developed before [18]. However, currently available nomograms do not take into account the interval between surgery and PORT. The nomogram developed in our study had a high C-index and large AUC, was well-calibrated, and could provide better predictive performance for individual patients.

Sex was found to be an independent predictor affecting long-term prognosis in our study. A large analysis based on the Surveillance, Epidemiology, and End Results (SEER) database also showed that female patients have significantly better outcomes than male patients, especially in ESCC [19]. We found that for every 1 cm increase in tumor length, the risk of death and disease progression relatively increased by 15.6% and 14.3%, respectively. Yendamuri et al. recommended that tumor length be incorporated into the current staging system for esophageal cancer to better evaluate long-term survival and determine postoperative treatment options [20]. In recent years, endoscopic surgery has been increasingly used instead of open surgery. Our research showed that endoscopic surgery has a survival advantage over open surgery. A meta-regression analysis identified 55 relevant studies that drew the conclusion that endoscopic surgery, due to its minimally invasive nature, can be recommended as a standard surgical approach for esophageal cancer [21]. The landmark RTOG 94–05 randomized controlled trial and the interim analysis found that increasing radiation dose from 50.4 to 64.8 Gy has no benefit in increasing locoregional control or OS [22]. In our research, the minimum radiation dose was 5000 cGy, and for each additional 1 cGy, the risk of death or disease progression was relatively increased by 1%.

A study on esophageal cancer found that pN+, increased number of positive nodes, and an increase in the pN classification were associated with a poor prognosis [23]. During esophagectomy, more extensive lymph node dissection provides benefit in terms of locoregional control and may also improve OS [24]. An analysis of esophageal cancer in the SEER database showed that the mortality rate of patients with 30 or more lymph nodes removed was significantly lower than that of patients with less than 30 lymph nodes removed [25]. Our multivariate analysis also showed that as the number of lymph nodes removed increased, both OS (p = 0.020) and PFS (p = 0.036) improved. Consistent with our results, a study has reported that LNR is an independent predictor of survival in esophageal cancer [26]. In our study, ROC curve analysis showed that the best cutoff value of LNR was 0.075, and patients with LNR < 0.075 were found to have better survival than patients with LNR ≥ 0.075.

Wong et al. discovered that adjuvant chemoradiotherapy can improve prognosis as compared to adjuvant radiotherapy alone [27]. We found that in patients who received adjuvant chemotherapy, the initiation of PORT tended to be delayed. A subgroup analysis of patients who received chemotherapy, stratified by time interval, showed that delayed PORT (≥48 days) significantly improved OS (p = 0.014) and PFS (p = 0.008). After incorporating the chemotherapy timing, the results suggested that provided R0 resection has been achieved, receiving 2–4 cycles of adjuvant chemotherapy between surgery and radiation therapy was beneficial. The potential benefits of this treatment schedule may include adequate wound healing, a smaller target volume for radiation therapy, sufficient time for tissue re-oxygenation, a vascular network that facilitates the passage of chemotherapy drugs, and earlier treatment of occult, disseminated micrometastatic disease. The above treatment schedule may lead to good local control and also reduce the occurrence of distant metastasis, though further research is needed to ensure that it has deterministic benefits.

Some limitations of our study should be noted. First, this study is a single-institution analysis, which may be subject to selection bias. Second, the study did not allow for the correction of all potential confounding factors, such as patients’ nutritional status and adverse effects of radiation therapy. Third, currently, there is wide variation in the sequence of adjuvant treatments for ESCC, including concurrent therapy, sequential therapy, and sandwich therapy. More prospective studies and clinical trials are needed to identify the treatment options with the maximum benefits.

Conclusions

In conclusion, the present study identified that delayed PORT (>48 days) was associated with better survival in patients with ESCC who had undergone R0 resection. Treatment with chemotherapy followed by PORT may achieve the best survival benefit. The nomograms we established provided a clear prognostic superiority, in terms of OS and PFS, over the 8th AJCC TNM staging.

Ethics approval and consent to participate

The current study was approved by the ethics committee of Fujian Medical University Cancer Hospital, Fuzhou, China (YKT2020-010-01) and conducted in accordance with the principles of the Declaration of Helsinki and its amendment. All patients provided written informed consent prior to treatment, and all the information was anonymized prior to analysis.

Funding

This work was supported by the Joint Funds for the Innovation of Science and Technology, Fujian Province (Grant number: 2018Y9111); and the Financial Foundation of Fujian Province (Grant number: (2019)827).

Data availability statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Author contributions statement

All authors helped to perform the research. MQL and J.-l. Li: Conceptualization, Methodology, Software, Writing - original draft preparation. ZKZ and XHC: Visualization, Investigation, Writing - review & editing.
Formal analysis, YQD and JYM: Project administration. SYH and YBH: Data curation, Investigation, Writing - review & editing. JCL: Funding acquisition, Supervision, Validation.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

[1] F. Bray, et al., Global cancer statistics 2018: GLOBOCAN estimates and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin. 68 (6) (2018) 394–424.
[2] J.B. Wheeler, C.E. Reed, Epidemiology of esophageal cancer, Surg. Clin. North Am. 92 (5) (2012) 1077–1087.
[3] H. Hou, et al., Survival of esophageal cancer in China: a pooled analysis on hospital-based studies from 2000 to 2018, Front. Oncol. 9 (2019) 548.
[4] J.B. Hulscher, et al., The recurrence pattern of esophageal carcinoma after transhiatal resection, J. Am. Coll. Surg. 191 (2) (2000) 143–148.
[5] D. Schreiber, et al., Impact of postoperative radiation after esophagectomy for esophageal cancer, J. Thorac. Oncol. 5 (2) (2010) 244–250.
[6] J. Kang, et al., Role of postoperative concurrent chemoradiotherapy for esophageal carcinoma: a meta-analysis of 2165 Patients, J. Cancer 9 (12) (2018) 584–593.
[7] W. Deng, et al., Postoperative radiotherapy in pathological T2-N0M0 thoracic esophageal squamous cell carcinoma: interim report of a prospective, phase iii, randomized controlled study, Oncologist 25 (4) (2020) e701–e708.
[8] J. Franko, S. McAvoy, Timing of esophagectomy after neoadjuvant chemoradiation treatment in squamous cell carcinoma, Surgery 164 (3) (2018) 455–459.
[9] D.N. Ranney, et al., Surgical resection after neoadjuvant chemoradiation for oesophageal adenocarcinoma: what is the optimal timing? Eur. J. Cardiothorac. Surg. 52 (3) (2017) 543–551.
[10] L.R. van der Werf, et al., Time interval between neoadjuvant chemoradiotherapy and surgery for oesophageal or junctional cancer: a nationwide study, Eur. J. Cancer 91 (2018) 76–85.
[11] Y. Wang, et al., Survival impact of delaying postoperative radiotherapy in patients with esophageal cancer, Transl. Oncol. 11 (6) (2018) 1358–1363.
[12] S. Yamada, et al., Prognostic impact of the period between surgery and postoperative irradiation in esophageal carcinoma, Tohoku J. Exp. Med. 172 (3) (1994) 275–282.
[13] A.L. Chin, et al., Survival impact of postoperative radiotherapy timing in pediatric and adolescent medulloblastoma, Neuro. Oncol. 20 (6) (2018) 1133–1141.
[14] E.M. Graboyes, et al., Effect of time to initiation of postoperative radiation therapy on survival in surgically managed head and neck cancer, Cancer 123 (24) (2017) 4841–4850.
[15] E. Shurell, et al., Delay in radiotherapy is associated with an increased risk of disease recurrence in women with ductal carcinoma in situ, Cancer 124 (1) (2018) 46–54.
[16] K. Sura, et al., Improved survival with increased time-to-radiation and sequential chemotherapy after surgery for pT2 non-small-cell lung cancer, Clin. Lung. Cancer 19 (2) (2018) e185–e194.
[17] Y. Ren, et al., Hypoxia modulates A431 cellular pathways association to tumor radioreistance and enhanced migration revealed by comprehensive proteomic and functional studies, Mol. Cell Proteomics 12 (2) (2013) 485–498.
[18] J. Cao, et al., Clinical nomogram for predicting survival of esophageal cancer patients after esophagectomy, Sci. Rep. 6 (2016) 26684.
[19] P. Bohanes, et al., Influence of sex on the survival of patients with esophageal cancer, J. Clin. Oncol. 30 (18) (2012) 2265–2272.
[20] S. Vendamuri, et al., Esophageal tumor length is independently associated with long-term survival, Cancer 115 (3) (2009) 508–516.
[21] E. Gottlieb-Vedi, et al., Long-term survival in esophageal cancer after minimally invasive compared to open esophagectomy: a systematic review and meta-analysis, Ann. Surg. 270 (6) (2019) 1055–1071.
[22] B.D. Minsky, et al., INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy, J. Clin. Oncol. 20 (5) (2002) 1167–1174.
[23] T.W. Rice, et al., Esophageal cancer: associations with (pN+) Lymph Node Metastases, Ann. Surg. 265 (1) (2017) 122–129.
[24] G. Darling, The role of lymphadenectomy in esophageal cancer, J. Surg. Oncol. 99 (4) (2009) 189–193.
[25] S.S. Groth, et al., Determination of the minimum number of lymph nodes to examine to maximize survival in patients with esophageal carcinoma: data from the surveil lance epidemiology and end results database, J. Thorac. Cardiovasc. Surg. 139 (3) (2010) 612–620.
[26] Z. Tan, et al., Can lymph node ratio replace pn categories in the tumor-node-metas tasis classification system for esophageal cancer? J. Thorac. Oncol. 9 (8) (2014) 1214–1221.
[27] A.T. Wong, et al., The impact of adjuvant postoperative radiation therapy and chemotherapy on survival after esophagectomy for esophageal carcinoma, Ann. Surg. 265 (6) (2017) 1146–1151.